Avaleht4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Viimane sulgemishind
2244,00 ¥
Tänane vahemik
2247,00 ¥ - 2274,00 ¥
Aasta vahemik
1921,00 ¥ - 2411,00 ¥
Turuväärtus
119,89 mld JPY
Keskmine maht
63,62 tuh
P/E suhe
11,85
Dividendimäär
1,99%
Põhibörs
TYO
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(JPY) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 20,97 mld | 14,11% |
Põhitegevusega seonduv kulu | 12,52 mld | 14,20% |
Puhastulu | 1,85 mld | −25,47% |
Puhaskasumimarginaal | 8,82 | −34,67% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 4,39 mld | 8,29% |
Tõhus maksumäär | 17,59% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(JPY) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 24,36 mld | 31,90% |
Kogu vara | 158,34 mld | 6,87% |
Kõik kohustused | 69,77 mld | −3,36% |
Kogu omakapital | 88,57 mld | — |
Emiteeritud aktsiate arv | 44,08 mln | — |
Hinna ja väärtuse suhe P/B | 1,12 | — |
Varade tasuvus | 4,06% | — |
Kapitali tasuvus | 4,89% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(JPY) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | 1,85 mld | −25,47% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Tegevjuht
Asutatud
22. dets 1955
Veebisait
Töötajate arv
1 777